In a report released yesterday, Mani Foroohar from SVB Securities maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report). The company’s shares closed yesterday at $7.68.
According to TipRanks, Foroohar is an analyst with an average return of -20.0% and a 32.42% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Moderna, and Mirum Pharmaceuticals.
Currently, the analyst consensus on BridgeBio Pharma is a Strong Buy with an average price target of $21.00, a 173.44% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $23.00 price target.
See the top stocks recommended by analysts >>
BBIO market cap is currently $1.18B and has a P/E ratio of -2.35.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BBIO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
Read More on BBIO:
- BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference
- BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1
- BridgeBio initiates Phase 3 trial CALIBRATE study of encaleret
- BridgeBio Pharma to Participate in November Investor Events
